Loading CRSP detail
Loading ticker data...
Loading CRSP detail
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Chart data unavailable
Steven Orr, Founder & CEO, Quasar Markets breaks down the five stocks Wall Street is mispricing and explains how he's finding real opportunities across AI, biotech, crypto and consumer right now.
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics has a pair of candidates that could transform how we address certain risk factors for cardiovascular conditions. They aren't the only promising candidates in the pipeline, either.
ZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, Apr 13 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events.
CRISPR Therapeutics is the second largest holding in Cathie Wood's Ark Innovation ETF. Incoming clinical trial data could send the stock soaring this year.
What if the biggest winners in biotech weren't the ones promising miracle cures, but the ones quietly supplying the picks and shovels — data that makes those cures possible?
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.51, moving +1.43% from the previous trading session.
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $48.81, denoting a +2.61% move from the preceding trading day.
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue growth provide a near-term path to profitability, with a strong foundation for future expansion. CRSP's in vivo cardiovascular pipeline, notably CTX310 and CTX320/321, targets large, underserved markets with disruptive one-time gene therapies.
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP now trades at the low end of its 4-year range, despite risk mitigation, a very promising pipeline, and a robust balance sheet, creating a compelling entry point. Casgevy's efficacy is very strong, with >90% response rates, but uptake has lagged due to burdensome preconditioning and patient concerns.
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) CEO Samarth Kulkarni sold 10,020 shares of the company's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the transaction, the chief executive officer directly owned 255,501 shares
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500® Continues a series of index inclusions across the U.S. equity benchmark landscape, reflecting AtaiBeckley's enhanced eligibility following its U.S. re-domiciliation and building on its addition to the Nasdaq Biotechnology Index in December 2025 NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 23, 2026. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026.
CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.
